Idiopathic Interstitial Pneumonia With Autoimmune Features - StatPearls... https://www.ncbi.nlm.nih.gov/books/NBK559021/?

report=printable

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.

Idiopathic Interstitial Pneumonia With Autoimmune Features

Authors

Mena Shehata1; Nancy J. Munn2.

Affiliations
1
Marshall University School of Medicine
2
Marshall University School of Medicine
Last Update: July 30, 2021.

Continuing Education Activity

This article is aimed at introducing idiopathic interstitial pneumonia with autoimmune features (IPAF) as a separate
entity under the umbrella of interstitial lung diseases (ILD). IPAF and other connective tissue disease-associated
interstitial lung disease (CTD-ILD) are essential to differentiate from IPF as the latter has a poor prognosis. Early
diagnosis is essential and multidisciplinary management with the involvement of a pulmonologist, radiologist,
pathologist, rheumatologist, and a thoracic surgeon is useful for consistent and accurate diagnosis and optimizing
patient outcomes. This activity reviews the evaluation and management of IPAF and highlights the role of the
interprofessional team in evaluating and improving care for patients with this condition.

Objectives:

!"Outline the definition of interstitial pneumonia with autoimmune features (IPAF).

!"Review the criteria for the diagnosis of interstitial pneumonia with autoimmune features (IPAF).

!"Explain the importance of interdisciplinary team communication for the diagnosis of interstitial pneumonia with
autoimmune features (IPAF).

!"Summarize the potential treatment for interstitial pneumonia with autoimmune features (IPAF).

Access free multiple choice questions on this topic.

Introduction
A contemporary joint research statement of the European Respiratory Society/American Thoracic Society (ERS/ATS)
proposed criteria for interstitial pneumonia with autoimmune features (IPAF) as an opening move in a trial to
uniformly describe and categorize a subset of patients with idiopathic interstitial pneumonia that exhibit evidence of
autoimmunity without meeting criteria for a defined connective tissue disease.[1] Before this consensus report, several
studies have focused on the presence of a particular subset of interstitial pneumonia, apparently idiopathic, associated
with one or more clinical and serological features, suggesting a possible underlying autoimmune disorder. Several
definitions and terminologies have been proposed for this specific form of interstitial pneumonia.[2][3][4]

The aforementioned joint consensus opinion was made possible via an international expert panel of thirteen
pulmonologists, four rheumatologists, one thoracic radiologist, and one pulmonary pathologist.[5] These
classifications were based on a combination of features from three domains: a clinical domain consisting of
extrathoracic elements, a serological domain with specific autoantibodies, and a morphological domain with imaging
patterns, histopathological findings, and multi-compartment involvement.

Etiology

1 de 8 14/3/22, 18:09
Idiopathic Interstitial Pneumonia With Autoimmune Features - StatPearls... https://www.ncbi.nlm.nih.gov/books/NBK559021/?report=printable

Interstitial lung disease (ILD) comprises of a large group of idiopathic diffuse processes that affect the lung
parenchyma. Connective tissue disease-associated lung disease (CTD-ILD) represents one of the most common causes
of ILD. Along with idiopathic pulmonary fibrosis (IPF), they both represent the majority of ILDs.[5] Since CTD-ILD
typically follows a better clinical course compared to IPF, and hence therapies differ substantially between them, an
accurate diagnosis is critical. Up to 30% of newly diagnosed ILD will be due to CTD.[6][7][8] This underscores the
importance of investigating all patients with ILD for possible underlying CTD.[5][8]

Epidemiology
It has been determined that up to 25% of patients with features of a systemic autoimmune disease do not fulfill the
American College of Rheumatology (ACR) classification criteria for connective tissue disease.[9] On the contrary, in
the absence of a defined CTD, 10-20% of patients with idiopathic interstitial pneumonia have systemic symptoms and
serological abnormalities suggestive of an autoimmune process. Therefore experts from different medical specialties
across the globe have conceptualized this entity as an undifferentiated CTD-associated ILD, lung-dominant CTD, and
autoimmune featured ILD, using different but overlapping criteria and terminology.[2][4][2]

It is not possible to accurately approximate the incidence and prevalence rates of ILD. Numerous prospective ILD
registries have been established to address this issue.[10] One study estimated incidence to be 30 cases of ILD for
every 100,000 annually. The overall prevalence is 80.9 per 100,000 in males and 67.2 per 100,000 annually diagnosed
in females.[11] The prevalence of idiopathic interstitial pneumonia with autoimmune features (IPAF) varies between 7
and 34% of all ILDs depending on the population studied and patient recruitment profile. Regarding demographic
characteristics, the mean age varies from 60-65 years, with balanced gender, although some studies reported a younger
mean age of 55 and predominance of white non-smoking women.[12][13][14] These characteristics are different from
those observed in CTD-ILD, where patients are predominantly younger females and from patients with IPF who tend
to be predominantly older males. IPAF patients are more frequently smokers or ex-smokers, unlike patients with
UCTD-ILD, likely related to a greater percentage of 30% of cases with a usual interstitial pneumonia (UIP) pattern
that meets IPAF criteria.[4][14]

Pathophysiology
The pathophysiology of idiopathic interstitial pneumonia with autoimmune features (IPAF) remains evasive, as no
specific studies have been conducted, and it is hypothesized that pathways involved in IPF or CTD-ILD would be
involved in IPAF. It is generally considered that pathophysiological studies are challenging to design in the absence of
clear diagnostic boundaries, and especially in the lack of consensus regarding IPAF being an entity.

In a study by Newton et al., differences were found between patients with IPAF and those with IPF or CTD-ILD about
leukocyte telomere length, MUC5B polymorphism, but not TOLLIP polymorphism.[15] Both telomere length and
MUC5B polymorphism were associated with survival. Fewer patients with IPAF and CTD-ILD had short telomere as
compared to IPF. Still, short telomere length in IPAF was associated with a faster decline in lung function and lung
transplantation, similar to IPF.[15] Although it is difficult to at this stage to fully understand the significance of these
observations, and it is not known whether the genetic markers may help to guide treatment indications in the future,
these results point to genetic differences between IPAF, IPF, and CTD-ILD.

History and Physical

Typically the first manifestation of ILD is the onset of progressive breathlessness with exertion, a persistent
nonproductive cough, or pulmonary symptoms associated with another disease, such as a connective tissue
disease. Prior to the consensus criteria for idiopathic interstitial pneumonia with autoimmune features (IPAF), there
were four different proposed terminologies in various articles used to describe non-typical ILD entities:

1) Undifferentiated CTD-ILD[2][11]

2 de 8 14/3/22, 18:09
Idiopathic Interstitial Pneumonia With Autoimmune Features - StatPearls... https://www.ncbi.nlm.nih.gov/books/NBK559021/?report=printable

2) Undifferentiated connective tissue disease—strict definition[11][3]

3) Lung dominant-connective tissue disease[4][11]

4) Autoimmune-featured interstitial lung disease (AIF-ILD)[11][16]

It wasn't until the2015 ERS/ATS consensus paper that certain criteria were advocated. The published IPAF criteria
(Table 1) required:

(1) Radiological or histopathological evidence of interstitial pneumonia and,

(2) Complete clinical evaluation excluding other etiologies for interstitial pneumonia and,

(3) Incomplete features of a defined CTD,

To meet the criteria for IPAF, cases must fulfill the three a priori requirements, in addition to a minimum of one
element from at least two of the following domains:[1]

A. Clinical domain (specific clinical features)

B. Serological domain (specific circulating autoantibodies)

C. Morphologic domain (specific chest imaging features, histopathological features, or multi-compartment

involvement)

According to three published cohorts, there was a significantly higher prevalence of patients meeting serological and
clinical criteria. Between 47 and 63% of IPAF patients had at least one clinical sign. The most common clinical signs
were the Raynaud phenomenon (28-39%), followed by the mechanic's hands (4-29%) and Gottron sign (5 to
18%).[17]

Evaluation
Clinical Domain: In this domain, particular clinical features suggestive of an underlying CTD are included. While
they are specific findings, their presence alone does not allow the diagnosis of a defined CTD. Among the clinical
domain features, physical signs include digital fissuring at the distal phalanges (mechanic’s hands), or ulceration at
these areas, inflamed joints, or multiple joint morning stiffness that lasts more than sixty minutes, Raynaud
phenomenon, palmar telangiectasia, not otherwise explained finger edema, and unexplained fixed rash on the fingers
extensor aspects (Gottron sign).[1][18] The task force intended to include signs and symptoms particular for
autoimmune etiologies but whose nonexistence does not exclude the existence of a CTD. The congregation also
advocated that, preferably, the presence of clinical features should be assessed on physical exams by experienced
providers and that self-reported symptoms should not be used unaided to identify clinical domain features.[1][8][18]

Serological Domain: Included in this domain autoantibodies with solid CTD connection (Table 1) and by requiring
moderately high titers for less specific autoantibodies, such as antinuclear antibodies ANA ≥ 1:320 or rheumatoid
factor (RF) at two or more than two times the higher level of normal.[8][18][19][20] Non-specific indicators of
inflammation, such as erythrocyte sedimentation rate or C- reactive protein, were excluded.[19] Since the
antineutrophil cytoplasmic antibody (ANCA) is related to vasculitis-associated ILD more so than ILD due to CTD, it
was omitted from idiopathic interstitial pneumonia with autoimmune features (IPAF) criteria.[8]

Morphological Domain: The morphologic domain is subdivided into three underlying sub-domains: radiographic,
pathologic, and multi-compartment.[8]

!"The radiographic subdomain describes patterns from high-resolution chest tomography (HRCT) that include
non-specific interstitial pneumonia (NSIP), organizing pneumonia (OP), and lymphocytic interstitial pneumonia
(LIP).[8][19][21] NSIP is the most detected pattern on HRCT in patients with CTD-ILD, and the presence of
NSIP, OP, or LIP patterns on HRCT poses additional consideration of an underlying autoimmune process.

3 de 8 14/3/22, 18:09
Idiopathic Interstitial Pneumonia With Autoimmune Features - StatPearls... https://www.ncbi.nlm.nih.gov/books/NBK559021/?report=printable

Although the UIP pattern on HRCT is the most common in rheumatoid arthritis-associated ILD and is also
encountered in other CTD-ILD, it was not given the equivalent influence as the other idiopathic interstitial
pneumonia (IIP) patterns as it is less specific for CTD.[1][8]

!"Pathological subdomain: Patients classified as IPAF had tissue specimens demonstrating non-specific interstitial
pneumonia, organizing pneumonia, interstitial lymphoid aggregates, or diffuse lymphoplasmacytic infiltrate.
[8][17][8] Again, although the UIP pattern can be seen in the setting of CTD, particularly rheumatoid arthritis, it
is not advocated in IPAF criteria given diminished specificity.[5]

!"Since CTD often has intrathoracic extra-parenchymal findings, this showed a need to add a multi-compartment
subdomain. Such manifestations incorporate inexplicable pericardial or pleural effusion or thickening,
pulmonary vasculopathy, and intrinsic airways disease.[8][11]

Treatment / Management
At present, it is unclear whether specific management distinct from that of IPF or CT-ILD is needed. Facts regarding
idiopathic interstitial pneumonia with autoimmune features (IPAF) treatment are merely limited to case series, and
further research is necessary to determine the optimal treatment approach in the IPAF population. As previously
acknowledged with other ILDs, pulmonary rehabilitation, long-term oxygen supplementation therapy if applicable,
and treatment of gastroesophageal reflux if existing is recommended.[22] There have been no randomized controlled
trials favoring immunomodulation in IPAF, and the proposed treatment strategies are inferred from CTD-ILD studies.
[11][23] In one study, patients with unclassifiable ILD, especially those meeting IPAF criteria in the non-UIP pattern,
intravenous pulse cyclophosphamide was suggested to stabilize lung function.[24] In that study, it was suggested that
those with fibrosing predominant pathology, might not benefit from corticosteroids and immunosuppressive drugs, as
their clinical behavior is more comparable to those with IPF.

Another large retrospective study of 125 patients with CTD-ILD encompassed nineteen patients with IPAF. In that
study, mycophenolate (MMF) was related to an improved FVC in all tested patients.[23][25] Different big case series
investigating the benefits of rituximab in intractable interstitial lung diseases incorporated nine patients with IPAF, all
of whom were managed with prednisone ± MMF before rituximab application. Of the five IPAF patients with pre- and
post-rituximab pulmonary function tests (PFTs), four of five had maintenance or improvement post rituximab.
[23][26] An ongoing randomized, controlled phase II trial of the role of pirfenidone in patients with fibrosing
undifferentiated ILD, including those who match criteria for IPAF, will be the first controlled study assessing a
possible therapeutic option in this subset of patients.[27]

The INBUILD trial suggests that nintedanib decreases the rate of ILD progression, as measured by forced vital
capacity (FVC) decline in patients who have a chronic fibrosing ILD and progressive phenotype, irrespective of the
underlying ILD diagnosis (including IPAF).[28] Whether the combination of immunosuppressive therapy and
antifibrotic drugs may be useful in subjects with IPAF will need to be explored in the future.

Differential Diagnosis
Idiopathic interstitial pneumonia with autoimmune features (IPAF) is an overlap between idiopathic interstitial
pneumonia and connective tissue disease-associated ILD, so the following conditions must be ruled out while making
a diagnosis of IPAF.

!"Idiopathic pulmonary fibrosis (IPF)

!"Connective tissue disease-associated ILD (CTD-ILD)

!"Cryptogenic organizing pneumonia (COP)

!"Idiopathic non-specific interstitial pneumonia (NSIP)

4 de 8 14/3/22, 18:09
Idiopathic Interstitial Pneumonia With Autoimmune Features - StatPearls... https://www.ncbi.nlm.nih.gov/books/NBK559021/?report=printable

!"Lymphocytic interstitial pneumonia (LIP)

Prognosis
Review of literature implies a better prognosis for patients with idiopathic interstitial pneumonia with autoimmune
features (IPAF) in comparison to patients with IPF yet marginally worse than patients with CTD-ILD. One study
demonstrated an expressively inferior survival in those meeting IPAF benchmarks when compared to a CTD-ILD
patient and barely slightly better survival compared to an IPF cohort.[8] In the same study, after stratifying the
premeditated population based on the occurrence of UIP on HRCT or solid lung biopsy, IPAF patients without UIP
had comparable survival as a CTD-ILD population. In contrast, those with UIP had an equivalent survival as an IPF
cohort.

Another study showed somewhat similar results with the survival of the modified IPAF cohort identical to that of
CTD-ILD (p=0.26), and significantly better than the IPF cohort (p=0.005).[29] Collins et al., also showed that patients
meeting the IPAF criteria revealed constancy in pulmonary static and dynamic function over a 1-year follow-up
period. Still, parallel trends were observed in CTD-ILD and IPF cohorts during this time.[30] With increased
documentation of patients with this disease category, more information about the prognosis shall be available.

Complications
Idiopathic interstitial pneumonia with autoimmune features (IPAF) is a progressive disease. If not diagnosed or treated
early it can progress to end-stage lung fibrosis. Other complications include

!"Progressive lung fibrosis

!"Pulmonary hypertension

!"Cor pulmonale

!"Hypoxemic respiratory failure requiring domiciliary oxygen

!"Depression/anxiety

Consultations
The diagnosis and management of idiopathic interstitial pneumonia with autoimmune features (IPAF) need a
multidisciplinary approach. The following specialties can manage these patients through teamwork.

!"Radiologist

!"Pulmonologist

!"Pathologist

!"Rheumatologist

!"Thoracic surgery (i.e. for solid lung biopsy)

Deterrence and Patient Education

Patients with idiopathic interstitial pneumonia with autoimmune features (IPAF) should be educated about their
disease.

!"Maintain a healthy weight

!"Smoking cessation

5 de 8 14/3/22, 18:09
Idiopathic Interstitial Pneumonia With Autoimmune Features - StatPearls... https://www.ncbi.nlm.nih.gov/books/NBK559021/?report=printable

!"Avoid any environmental or occupational exposure that exacerbates lung disease

!"Immunizations especially pneumococcal and annual influenza vaccination

!"Pulmonary rehabilitation

By following these points disease progression can be halted and complications can be minimized.

Enhancing Healthcare Team Outcomes

The definition of idiopathic interstitial pneumonia with autoimmune features (IPAF) has already shed light on the
importance of a thorough evaluation of patients with apparently idiopathic ILD and the value of the interaction
between medical specialties. IPAF and other CTD-ILD are essential to differentiate from IPF as the latter has a poor
prognosis. Early diagnosis is crucial and multidisciplinary management with the involvement of a pulmonologist,
radiologist, pathologist, rheumatologist and, a thoracic surgeon and is useful for the approach to IPAF, especially for
consistent and accurate diagnosis and optimizing patient outcomes.

Review Questions

!"Access free multiple choice questions on this topic.

!"Comment on this article.

References
1. Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson
EL, Mosca M, Noth I, Richeldi L, Strek ME, Swigris JJ, Wells AU, West SG, Collard HR, Cottin V., “ERS/ATS
Task Force on Undifferentiated Forms of CTD-ILD” An official European Respiratory Society/American Thoracic
Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015 Oct;46(4):976-87.
[PubMed: 26160873]
2. Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD, King TE. Idiopathic nonspecific
interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care
Med. 2007 Oct 01;176(7):691-7. [PMC free article: PMC1994238] [PubMed: 17556720]
3. Corte TJ, Copley SJ, Desai SR, Zappala CJ, Hansell DM, Nicholson AG, Colby TV, Renzoni E, Maher TM, Wells
AU. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J. 2012
Mar;39(3):661-8. [PubMed: 21920896]
4. Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung
disease: a call for clarification. Chest. 2010 Aug;138(2):251-6. [PMC free article: PMC3662187] [PubMed:
20682528]
5. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F,
Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L,
Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ,
Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC., American Thoracic Society, European
Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic
Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med.
2018 Sep 01;198(5):e44-e68. [PubMed: 30168753]
6. Mittoo S, Gelber AC, Christopher-Stine L, Horton MR, Lechtzin N, Danoff SK. Ascertainment of collagen
vascular disease in patients presenting with interstitial lung disease. Respir Med. 2009 Aug;103(8):1152-8.
[PubMed: 19304475]
7. Kligerman SJ, Groshong S, Brown KK, Lynch DA. Nonspecific interstitial pneumonia: radiologic, clinical, and
pathologic considerations. Radiographics. 2009 Jan-Feb;29(1):73-87. [PubMed: 19168837]
8. Lee CT, Oldham JM. Interstitial Pneumonia with Autoimmune Features: Overview of proposed criteria and recent

6 de 8 14/3/22, 18:09
Idiopathic Interstitial Pneumonia With Autoimmune Features - StatPearls... https://www.ncbi.nlm.nih.gov/books/NBK559021/?report=printable

cohort characterization. Clin Pulm Med. 2017 Sep;24(5):191-196. [PMC free article: PMC5739083] [PubMed:
29276366]
9. Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature
and a proposal for preliminary classification criteria. Clin Exp Rheumatol. 1999 Sep-Oct;17(5):615-20. [PubMed:
10544849]
10. Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer.
Br J Cancer. 2004 Aug;91 Suppl 2:S3-10. [PMC free article: PMC2750810] [PubMed: 15340372]
11. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir
Crit Care Med. 1994 Oct;150(4):967-72. [PubMed: 7921471]
12. Ahmad K, Barba T, Gamondes D, Ginoux M, Khouatra C, Spagnolo P, Strek M, Thivolet-Béjui F, Traclet J,
Cottin V. Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics
and outcome in a series of 57 patients. Respir Med. 2017 Feb;123:56-62. [PubMed: 28137497]
13. Chartrand S, Swigris JJ, Stanchev L, Lee JS, Brown KK, Fischer A. Clinical features and natural history of
interstitial pneumonia with autoimmune features: A single center experience. Respir Med. 2016 Oct;119:150-154.
[PubMed: 27692137]
14. Oldham JM, Adegunsoye A, Valenzi E, Lee C, Witt L, Chen L, Husain AN, Montner S, Chung JH, Cottin V,
Fischer A, Noth I, Vij R, Strek ME. Characterisation of patients with interstitial pneumonia with autoimmune
features. Eur Respir J. 2016 Jun;47(6):1767-75. [PMC free article: PMC5515625] [PubMed: 27103387]
15. Newton CA, Oldham JM, Ley B, Anand V, Adegunsoye A, Liu G, Batra K, Torrealba J, Kozlitina J, Glazer C,
Strek ME, Wolters PJ, Noth I, Garcia CK. Telomere length and genetic variant associations with interstitial lung
disease progression and survival. Eur Respir J. 2019 Apr;53(4) [PMC free article: PMC6612265] [PubMed:
30635297]
16. Fernandes L, Nasser M, Ahmad K, Cottin V. Interstitial Pneumonia With Autoimmune Features (IPAF). Front
Med (Lausanne). 2019;6:209. [PMC free article: PMC6798044] [PubMed: 31681774]
17. Sambataro G, Sambataro D, Torrisi SE, Vancheri A, Colaci M, Pavone M, Pignataro F, Del Papa N, Palmucci S,
Vancheri C. Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with
Autoimmune Features (IPAF) patients. Respir Med. 2019 Apr;150:154-160. [PubMed: 30961944]
18. Fischer A. Interstitial Pneumonia with Autoimmune Features. Clin Chest Med. 2019 Sep;40(3):609-616.
[PubMed: 31376895]
19. Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011
Nov;140(5):1292-1299. [PMC free article: PMC3205845] [PubMed: 21565966]
20. Ito Y, Arita M, Kumagai S, Takei R, Noyama M, Tokioka F, Nishimura K, Koyama T, Notohara K, Ishida T.
Serological and morphological prognostic factors in patients with interstitial pneumonia with autoimmune
features. BMC Pulm Med. 2017 Aug 14;17(1):111. [PMC free article: PMC5554971] [PubMed: 28807021]
21. Jee AS, Adelstein S, Bleasel J, Keir GJ, Nguyen M, Sahhar J, Youssef P, Corte TJ. Role of Autoantibodies in the
Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features
(IPAF). J Clin Med. 2017 May 04;6(5) [PMC free article: PMC5447942] [PubMed: 28471413]
22. Adegunsoye A, Oldham JM, Valenzi E, Lee C, Witt LJ, Chen L, Montner S, Chung JH, Noth I, Vij R, Strek ME,
Husain AN. Interstitial Pneumonia With Autoimmune Features: Value of Histopathology. Arch Pathol Lab Med.
2017 Jul;141(7):960-969. [PMC free article: PMC5554445] [PubMed: 28467213]
23. Cottin V, Crestani B, Cadranel J, Cordier JF, Marchand-Adam S, Prévot G, Wallaert B, Bergot E, Camus P,
Dalphin JC, Dromer C, Gomez E, Israel-Biet D, Jouneau S, Kessler R, Marquette CH, Reynaud-Gaubert M,
Aguilaniu B, Bonnet D, Carré P, Danel C, Faivre JB, Ferretti G, Just N, Lebargy F, Philippe B, Terrioux P,
Thivolet-Béjui F, Trumbic B, Valeyre D. French practical guidelines for the diagnosis and management of
idiopathic pulmonary fibrosis - 2017 update. Full-length version. Rev Mal Respir. 2017 Oct;34(8):900-968.
[PubMed: 28939155]
24. Wilfong EM, Lentz RJ, Guttentag A, Tolle JJ, Johnson JE, Kropski JA, Kendall PL, Blackwell TS, Crofford LJ.
Interstitial Pneumonia With Autoimmune Features: An Emerging Challenge at the Intersection of Rheumatology

7 de 8 14/3/22, 18:09
Idiopathic Interstitial Pneumonia With Autoimmune Features - StatPearls... https://www.ncbi.nlm.nih.gov/books/NBK559021/?report=printable

and Pulmonology. Arthritis Rheumatol. 2018 Dec;70(12):1901-1913. [PMC free article: PMC6261671]
[PubMed: 30058242]
25. Wiertz IA, van Moorsel CHM, Vorselaars ADM, Quanjel MJR, Grutters JC. Cyclophosphamide in steroid
refractory unclassifiable idiopathic interstitial pneumonia and interstitial pneumonia with autoimmune features
(IPAF). Eur Respir J. 2018 Apr;51(4) [PubMed: 29496758]
26. Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, Huie TJ, Krishnamoorthy
M, Meehan RT, Olson AL, Solomon JJ, Swigris JJ. Mycophenolate mofetil improves lung function in connective
tissue disease-associated interstitial lung disease. J Rheumatol. 2013 May;40(5):640-6. [PMC free article:
PMC3676865] [PubMed: 23457378]
27. Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells
AU, Renzoni EA. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014
Apr;19(3):353-9. [PubMed: 24286447]
28. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Cottin
V. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-
blind, randomised, placebo-controlled phase II trial. BMJ Open Respir Res. 2018;5(1):e000289. [PMC free
article: PMC6135451] [PubMed: 30233802]
29. Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser
S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M., INBUILD trial investigators. Nintedanib in
patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease
diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet
Respir Med. 2020 May;8(5):453-460. [PubMed: 32145830]
30. Collins BF, Spiekerman CF, Shaw MA, Ho LA, Hayes J, Spada CA, Stamato CM, Raghu G. Idiopathic
Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year. Chest. 2017
Jul;152(1):103-112. [PMC free article: PMC6026269] [PubMed: 28300570]

Copyright © 2022, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/),
which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original
author(s) and the source, a link is provided to the Creative Commons license, and any changes made are indicated.

Bookshelf ID: NBK559021 PMID: 32644447

8 de 8 14/3/22, 18:09